ClinicalTrials.gg
CompletedNCT04151212Updated Oct 9, 2026

A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration

A Phase 1 interventional study of BAT5906 injection in Age-related Macular Degeneration, sponsored by Bio-Thera Solutions. Completed at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Bio-Thera Solutions · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2018, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
69th of 91
24 · median 62
Started
2018
with 9 others
Phase 1
20 of 106
5 open now
Registered
36th of 106
by date
Lead sponsor
3 of 106
Bio-Thera Solutions

Among the 106 studies in Macular Degeneration with a site in China, this one is the 69th largest by enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2018, is one of 20 in phase 1, and was the 36th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.

Read the detailed description

The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates.

The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the pharmacodynamics and therapeutic efficacy profile of BAT5906.

03

Conditions studied

  • Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 50-80 years old .
  • Signing the form and able and willing to comply with all treatment and follow-up study procedures.
  • The study eye must meet all the following inclusion criteria: To be diagnosed as wet age related macular degeneration, and there are still active lesions currently;Total lesion size of ≤30mm2( 12 disc areas);Best corrected visual acuity ≤70 Early Treatment of Diabetic Retinopathy ;Study letters (≤20/40) in the study eye.
  • Best corrected visual acuity ≥34 Early Treatment of Diabetic Retinopathy Study letters (≥20/200) . in the non-study eye.

Exclusion criteria

Exclusion Criteria:

  • There are atrophy of the ground pattern involving the fovea, scar or fibrosis, macular anterior membrane, rigid exudation under dense fovea, RPE tear in the study eye.
  • Retinal hemorrhage ≥4 disc area in the study eye.
  • Dioptric media turbid or the pupil cannot be dilated were significant interference with the detection of vision, the evaluation of the anterior segment and fundus in the study eye.
  • Evidence of ocular disease other than exudative AMD in the study eye that may confound the outcome of the study (e.g.,Retinal vein occlusion, uveitis, vascular striatum, pathological myopia, retinal detachment, macular hole, toxoplasmosis, optic nerve disease etc).
  • History of vitrectomy surgery\macular transposition\glaucoma filtration in the study eye.
  • Photodynamic therapy(PDT), in macular area laser photocoagulation therapy, transpermary hyperthermia(TTT), and other operations for AMD within 3 months prior to screening visit in the study eye.
  • History of extraocula surgeryr within 1 months or cataract surgery within 3 months prior to screening visit in the study eye.
  • Aphakia(exclusive of intraocular lens) or rupture of posterior capsule( within1 months prior to the YAG laser retrovesiculotomy (after the artificial crystal), was excluded) in the study eye.
  • APD in the study eye or pseudocyst stripping syndrome in either eye.
  • Intravitrea or Systemicl anti-VEGF injection (ranibizumab, aflibercept, bevacizumab or Conbercept etc) in either eye within 3 months prior to screening visit.
  • Under the conjunctiva,intravitreal or periocular , within 3 months prior to screening visit in either eye.
  • vitreous hemorrhage within 3 months prior to screening Visit in either eye.
  • Ocular or periocular infection in either eye.
  • History of glaucoma in either eye.
  • Visudyne (verteporfin) photodynamic therapy within 1 months prior to screening Visit in non-study eye.
  • Currently in use or may be required to use systemic drugs that cause crystal toxicity or retinal toxicity, such as Deferoxamine, chloroquine/ hydroxychloroquine, phenothiazine and ethambutol or tamoxifen etc.
  • Have an allergic reaction or history of allergic reactions to fluorescein sodium and indocyanine green, an allergic history to therapeutic or diagnostic protein products, an allergic reaction to more than two drugs or non-drug factors, or allergic reactions to any monoclonal antibody.
  • Patients with diabetic retinopathy or the diabetic patient who have glycosylated? >10%.
  • Patients who have undergone any surgical operation within 1 month prior screening; or/and there are unhealed wounds, ulcers, fractures etc.
  • Systemic infectious diseases with clinical significance requiring oral, intramuscular or Patients withintravenous administration.
  • Myocardial infarction, cerebral infarction and angina pectoris within 6 months prior to screening visit.
  • Patients with active disseminated intravascular coagulation and obvious bleeding tendency were screened within 3 months before the screening, or they were treated with anticoagulant and antiplatelet therapy other than aspirin/NSAIDs within 14 days before the screening.
  • Patients with Systemic immune disease ,including but not limited to:

hyperthyroidism, hypothyroidism,vitiligo, dry-syndrome, ankylosing spondylitis, systemic nephritis, (HIV).

  • Blood pressure control is not ideal or pre-hypertension.
  • Any uncontrollable clinical problems (Serious mental, nervous, cardiovascular and respiratory diseases and malignant tumors).
  • Abnormal liver and kidney function.
  • Blood coagulation is abnormal.
  • Patients with AIDS, syphilis or active hepatitis.
  • Women are not using effective or in pregnancy,lactation.
  • Clinical trials of any trial medication or any other experimental or experimental therapy may be performed within 3 months prior to screening.
  • Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BAT5906 injection

    Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.

    Drug: BAT5906 injection

Interventions

  • Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection

    Also known as: No Other Intervention Names

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT)

    Safety and tolerability endpoint

    Time frame: 2 weeks

  2. Maximum tolerated dosed(MTD)

    Safety and tolerability endpoint

    Time frame: 0-70days

  3. Area under the curve(AUC0-t, AUC0-inf)

    Pharmacokinetic endpoint Pharmacokinetic endpoint

    Time frame: 0-70days

  4. Maximum serum drug concentration(Cmax)

    Pharmacokinetic endpoint Pharmacokinetic endpoint

    Time frame: 0-70days

  5. Half-life period(t1/2)

    Pharmacokinetic endpoint

    Time frame: 0-70days

  6. Maximum serum drug time(Tmax)

    Pharmacokinetic endpoint

    Time frame: 0-70days

  7. Plasma clearance(CL)

    Pharmacokinetic endpoint

    Time frame: 0-70days

Secondary outcomes

  1. Anti-drug antibodies(ADA)

    Immunogenic endpoint

    Time frame: 0-70days

  2. Best correct vision(BCVA)

    Effective endpoint

    Time frame: 0-70days

  3. Central Retinal thickness(CRT)

    Effective endpoint

    Time frame: 0-70days

  4. VEGF concentration

    Pharmacodynamics endpoint

    Time frame: 0-70days

07

Study locations

1 site
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Feb 2021, 27 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 27 months is above that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 5, 2019
StartActual
Oct 30, 2018
Primary completionActual
Feb 28, 2021
CompletionActual
Apr 30, 2021
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04151212
Responsible party
Sponsor
First posted
Nov 5, 2019
Start date
Oct 30, 2018
Primary completion
Feb 28, 2021
Completion
Apr 30, 2021
Last update
Oct 9, 2026

Study contacts

Youxin Chen
principal investigator · Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BAT5906

Start the discussion